НАУКОВА РОБОТА

1. Microbiological characteristic of the experimental use of “Autobiotic” on the model of antibiotic – induced dysbiosis in old rats / T. Ivakhniuk, O. Makarenko, Yu. Ivakhniuk, O. Molozhava // Modern Science –Moderní věda : Prague, Czech Republic. – 2018. – № 6. – Р. 107-113.

2. In vitro test-research of the indigenous intestinal microflora of the patients with Alzheimer disease / T. Ivakhniuk, Yu. Ivakhniuk, O. Makarenko, O. Molozhva, R. Dovgan // Modern Science –Moderní věda : Prague, Czech Republic. – 2019. – № 4. – Р. 136-142.

3. Роль мутацій гена PIK3CA в розвитку раку грудної залози (огляд літератури) / А.О. Привалова, І.О. Винниченко, В.Ю. Гарбузова, О.І. Винниченко, Ю.В. Москаленко // Запорізький медичний журнал. – 2020. – Т. 22, №4(121). – С. 554-560. https://doi.org/10.14739/2310-1210.2020.4.208402

4.Kuzenko O, Kuzenko Ye., Demin Yu. Enterosgel role in neurodegenerative changes in the retina rats under the influence of Cr (VI) – induced retinopathy by study morphological changes in dynamic. ScienceRise:Medical Science. 2021; 1(40): 14-20

5. Кузенко О.В., Кузенко Е.В., Дьомін Ю.А. Дослідження протекторних властивостей гідрогелю метилкремнієвої кислоти щодо нейротоксичності, індукованої Cr(VI) в зоровому нерві щурів. Офтальмологічний журнал. 2021; 1: 62-69.

6. Targeted therapy for non-small cell lung cancer focus on EGFR oncogenic mutation (literature review)/O. M. Smorodska, Yu. V. Moskalenko, I. O. Vynnychenko, O. I.[et al.] // Medicni perspektivi.- 2021 – Т. 26, № 2.- p. 8-11.

Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId=24781268000

h-index: 20

ORCID ID: https://orcid.org/0000-0002-2339-6509

1. Роль мутацій гена PIK3CA в розвитку раку грудної залози (огляд літератури) / А.О. Привалова, І.О. Винниченко, В.Ю. Гарбузова, О.І. Винниченко, Ю.В. Москаленко // Запорізький медичний журнал. – 2020. – Т. 22, №4(121). – С. 554-560. https://doi.org/10.14739/2310-1210.2020.4.208402
2. Targeted therapy for non-small cell lung cancer focus on EGFR oncogenic mutation (literature review)/O. M. Smorodska, Yu. V. Moskalenko, I. O. Vynnychenko, O. I.[et al.] // Medicni perspektivi.- 2021 – Т. 26, № 2.- p. 8-11.
3. Moskalenko Y, Kurochkin A, Vynnychenko I, Kravets O, Piddubnyi A, Moskalenko R, Potapov O. Toluidine blue for the detection of sentinel lymph nodes in patients with thyroid cancer. Contemp Oncol (Pozn). 2022;26(4):259-267. doi: 10.5114/wo.2022.124585. Epub 2022 Dec 30. PMID: 36816393; PMCID: PMC9933357.
4. Shah, M. A., Udrea, A. A., Bondarenko, I., Mansoor, W., Sánchez, R. G., Sarosiek, T., … & Ajani, J. A. (2022). Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers, 14(5), 1168.
5. Bedke, J., Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Waddell, T., … & Powles, T. (2022). Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. European Urology, 82(4), 427-439.
6. de Castro Jr, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C., Yamamoto, N., … & NEPTUNE Investigators. (2023). NEPTUNE: phase 3 study of first-line Durvalumab plus tremelimumab in patients with metastatic NSCLC. Journal of Thoracic Oncology, 18(1), 106-119.
7. Psyrri, A., Fayette, J., Harrington, K., Gillison, M., Ahn, M. J., Takahashi, S., … & KESTREL Investigators. (2023). Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Annals of Oncology, 34(3), 262-274.
8. Ren, S., Feng, J., Ma, S., Chen, H., Ma, Z., Huang, C., … & Zhou, C. (2023). KEYNOTE‐033: randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC. International Journal of Cancer, 153(3), 623-634.
9. Plimack, E. R., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., … & Rini, B. I. (2023). Pembrolizumab Plus Axitinib Versus Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma: 43-Month Follow-up of the Phase 3 KEYNOTE-426 Study. European Urology, 84(5), 449-454.
10. Plimack, E. R., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., … & Rini, B. I. (2023). Corrigendum to” Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study”[Eur. (2023)]. European urology, 84(5), e123-e124.

11. Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] Primack, Elizabeth R. et al. European Urology, Volume 84, Issue 5, e123 – e124.

12. Felip E, Altorki N,
    Zhou C, Vallières E, Csoszi T, Vynnychenko IO, Goloborodko O, Rittmeyer A, Reck
    M, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Fu C, Ballinger
    M, Deng Y, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA; IMpower010 Study
    Investigators. Five-Year
    Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage
    IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized,
    Phase III Trial. J Clin Oncol. 2025 Jul
    20;43(21):2343-2349. doi: 10.1200/JCO-24-01681. 

13. Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T,
    Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, de
    Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, Wu S, Markensohn
    J, Zhang Y, Loboda A, Vajdi A, Perini RF, Burgents J, Powles T. Pembrolizumab
    plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma:
    5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial. Nat
    Med. 2025 Aug 1. doi: 10.1038/s41591-025-03867-5. 

14. Kostiuchenko, V.,
    Vynnychenko, I., Moskalenko, Y., & Pohorila, V. (2025). Detection of
    postoperative recurrence in colorectal cancer: Exploring the value of liquid
    biopsy. Regulatory Mechanisms in Biosystems, 16(1),
    e25020. https://doi.org/10.15421/0225020

Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId= 57193309806

h-index: 4

ORCID ID: https://orcid.org/0000-0002-5398-0298

Research ID: ABG-1458-2020

Google Scholar: https://scholar.google.com.ua/citations?hl=uk&user=8tetJHcAAAAJ

h-index: 2

Research Gate: https://www.researchgate.net/profile/Yuliia-Moskalenko-2

1. Роль мутацій гена PIK3CA в розвитку раку грудної залози (огляд літератури)/ А.О. Привалова, І.О. Винниченко, Ю.В. Москаленко [та інші] // Запорізький медичний журнал. – Запоріжжя : Запорізький державний медичний університет, 2020. – Т. 22, № 4. – С. 554–560.
2. Targeted therapy for non-small cell lung cancer focus on EGFR oncogenic mutation (literature review)/O. M. Smorodska, Yu. V. Moskalenko, I. O. Vynnychenko, O. I.[et al.] // Medicni perspektivi.- 2021 – Т. 26, № 2.- p. 8-11.
3. Smorodska O, Moskalenko Y, Vynnychenko I, Vynnychenko O, Kostuchenko V. Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review). Med. perspekt. [Internet]. 2021Jun.18 [cited 2021Sep.20];26(2):4-11. Available from: http://journals.uran.ua/index.php/2307-0404/article/view/234379
4. Piddubnyi, A., Kolomiiets, O., Danilchenko, S., Stepanenko, A., Moskalenko, Y., & Moskalenko, R. (2023). The Prospects of Using Structural Phase Analysis of Microcalcifications in Breast Cancer Diagnostics. Diagnostics, 13(4), 737.
5. Moskalenko, Y. (2024). Biological mechanisms of resistance to immune checkpoint inhibitors and overcoming this resistance: Challenges in medical oncology. Regulatory Mechanisms in Biosystems, 15(1), 83-91. https://doi.org/10.15421/022412. 
6. Vynnychenko OI, Lakhtaryna RY, Moskalenko YV. Breast cancer in Ukraine during the last decade. Світ медицини та біології. 2024; 90(4): 30–33. doi: 10.26724/2079-8334-2024-4-90-30-33. 
7. Vynnychenko O, Moskalenko Y, Moskalenko R. Markers of inflammation as predictors of efficacy of trastuzumab therapy in HER2-positive metastatic breast cancer patients. Regulatory Mechanisms in Biosystems. 2025; 16(1): e25003. doi:10.15421/0225003.
8. Moskalenko Y., Kravets O., Kovchun V. Clinical outcomes of concurrent use of corticosteroids and immune checkpoint inhibitors in oncology. Regul Mech Biosyst. 2025;16(2):e25062 doi: 10.15421/0225062
9. Moskalenko Y, Kovchun V, Bohdanov A, Budko V, Yazykov O. Visceral Adipose Tissue Radiodensity as a Potential Biomarker of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer Patients. Galician med. j. 2025;32(3):e-GMJ2025-A21. доступний у: https://doi.org/10.21802/e-GMJ2025-A21.
10. Moskalenko Y, Yazykov O, Vasylieva O, Smiian K, Ivakhniuk T, Budko H, Moskalenko R. The Impact of Age on the Effectiveness of Immune Checkpoint Inhibitors Therapy in Patients with Metastatic Non-Small-Cell Lung Cancer. Geriatrics (Basel). 2025 Jun 27;10(4):85. doi: 10.3390/geriatrics10040085.
11. Kostiuchenko, V., Vynnychenko, I., Moskalenko, Y., & Pohorila, V. (2025). Detection of postoperative recurrence in colorectal cancer: Exploring the value of liquid biopsy. Regulatory Mechanisms in Biosystems, 16(1), e25020. https://doi.org/10.15421/0225020

12. Kozakov D, Kobyliak N, Livshun S, Seleznov O, Koshyk O, Matvieieva A, Shparyk Y, Kolesnik O, Moskalenko Y, Vynnychenko O, Moskalenko R, Kropyvko S, Khmel A, Shkarupii B, Sulaieva O. Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study. Front Med (Lausanne). 2025 Jul 30;12:1558016. doi: 10.3389/fmed.2025.1558016. 

13. Vynnychenko OІ, Moskalenko YuV, Piddubnyi AM, Moskalenko RA. Distribution of M1 and M2 macrophages and their impact on survival in non-small cell lung cancer. Reports of Morphology. 2025; 31(1): 37–44. doi: 10.31393/morphology-journal-2025-31(1)-05.

14. Vynnychenko O, Moskalenko Y, Yazykov O, Tymchenko I, Seleznov O, Sulaieva O, Moskalenko R. Prognostic role of STAT6 in patients with non-small cell lung cancer. Regulatory Mechanisms in Biosystems. 2024; 15(4): 868–874. doi: 10.15421/0224125.

15. Vynnychenko O, Moskalenko R. Biological mechanisms of resistance to trastuzumab and ways to overcome them: Modern problems of clinical oncology. Regulatory Mechanisms in Biosystems. 2024; 15(2): 345–352. doi: 10.15421/022449.

Scopus Author ID: 

h-index: 0

ORCID ID: 

1. Vynnychenko OI, Lakhtaryna RY, Moskalenko YV. Breast cancer in Ukraine during the last decade. Світ медицини та біології. 2024; 90(4): 30–33. doi: 10.26724/2079-8334-2024-4-90-30-33.

2. Savchenko T, Lakhtaryna R, Denysenko A, Dovbysh A, Coupland SE, Moskalenko R. An Information-Extreme Algorithm for Universal Nuclear Feature-Driven Automated Classification of Breast Cancer Cells. Diagnostics (Basel). 2025 May 30;15(11):1389. doi: 10.3390/diagnostics15111389. 

Scopus Author ID: 57720919100

h-index: 1

ORCID ID: https://orcid.org/0000-0002-9577-0272

Google Scholar:https://scholar.google.com/citations?view_op=list_works&hl=uk&user=ouTGJgcAAAAJ

Research Gate:https://www.researchgate.net/profile/Kovchun-Viktor

1. Kachkovska V, Kovchun A, Kovchun V., Prystupa L.The role of Low-Dose CT scan in the early diagnosis of malignant neoplasms of different localization. European Respiratory Journal 2023, 62: PA5348.

2. Moskalenko Y., Kravets O., Kovchun V. Clinical outcomes of concurrent use of corticosteroids and immune checkpoint inhibitors in oncology. Regul Mech Biosyst. 2025;16(2):e25062 doi: 10.15421/0225062 

3. Moskalenko Y, Kovchun V, Bohdanov A, Budko V, Yazykov O. Visceral Adipose Tissue Radiodensity as a Potential Biomarker of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer Patients. Galician med. j. 2025;32(3):e-GMJ2025-A21. доступний у: https://doi.org/10.21802/e-GMJ2025-A21.